JP2002508747A - 小胞複合体並びにその作製及び使用法 - Google Patents
小胞複合体並びにその作製及び使用法Info
- Publication number
- JP2002508747A JP2002508747A JP54741798A JP54741798A JP2002508747A JP 2002508747 A JP2002508747 A JP 2002508747A JP 54741798 A JP54741798 A JP 54741798A JP 54741798 A JP54741798 A JP 54741798A JP 2002508747 A JP2002508747 A JP 2002508747A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- protein
- local anesthetic
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 167
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 155
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 146
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 137
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 137
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 230000028993 immune response Effects 0.000 claims abstract description 31
- 230000001939 inductive effect Effects 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 62
- 108020004414 DNA Proteins 0.000 claims description 59
- 230000002163 immunogen Effects 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 230000001225 therapeutic effect Effects 0.000 claims description 32
- 230000001717 pathogenic effect Effects 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 230000007935 neutral effect Effects 0.000 claims description 24
- 125000002091 cationic group Chemical group 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 19
- 230000003463 hyperproliferative effect Effects 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 229960003150 bupivacaine Drugs 0.000 claims description 17
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- -1 cationic lipid Chemical class 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 239000003945 anionic surfactant Substances 0.000 claims description 6
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000446313 Lamella Species 0.000 claims description 2
- 108091005461 Nucleic proteins Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- 238000002690 local anesthesia Methods 0.000 claims 1
- 235000018553 tannin Nutrition 0.000 claims 1
- 229920001864 tannin Polymers 0.000 claims 1
- 239000001648 tannin Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 72
- 229960005015 local anesthetics Drugs 0.000 description 34
- 241000700605 Viruses Species 0.000 description 26
- 239000012528 membrane Substances 0.000 description 22
- 244000052769 pathogen Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 210000004379 membrane Anatomy 0.000 description 16
- 238000004626 scanning electron microscopy Methods 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 15
- 230000002209 hydrophobic effect Effects 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 13
- 230000004957 immunoregulator effect Effects 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 238000000502 dialysis Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000008488 polyadenylation Effects 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 125000000129 anionic group Chemical group 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000712003 Human respirovirus 3 Species 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960003976 etidocaine Drugs 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 229960004919 procaine Drugs 0.000 description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960002372 tetracaine Drugs 0.000 description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 230000007332 vesicle formation Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 206010061041 Chlamydial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 206010014614 Encephalitis western equine Diseases 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 201000006353 Filariasis Diseases 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241001559186 Human rubulavirus 4 Species 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 241000701037 Rhadinovirus Species 0.000 description 2
- 208000034712 Rickettsia Infections Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 2
- 201000005806 Western equine encephalitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 229940105270 carbocaine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229960002409 mepivacaine Drugs 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960000244 procainamide Drugs 0.000 description 2
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000701021 Betaherpesvirinae Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 208000008889 California Encephalitis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000588877 Eikenella Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014584 Encephalitis california Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010053025 Endemic syphilis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 208000002613 Feline Panleukopenia Diseases 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000701915 Feline panleukopenia virus Species 0.000 description 1
- 241000701925 Feline parvovirus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241001559187 Human rubulavirus 2 Species 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 201000009908 La Crosse encephalitis Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000701043 Lymphocryptovirus Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000701034 Muromegalovirus Species 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000006007 Nairobi Sheep Disease Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001455645 Rabbitpox virus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000701067 Varicellovirus Species 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 208000003836 bluetongue Diseases 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 244000000066 protist pathogen Species 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 244000079416 protozoan pathogen Species 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 201000009482 yaws Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/905—Specially adapted for travel through blood circulatory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4512297P | 1997-04-30 | 1997-04-30 | |
| US60/045,122 | 1997-04-30 | ||
| PCT/US1998/008799 WO1998048780A1 (en) | 1997-04-30 | 1998-04-30 | Vesicular complexes and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002508747A true JP2002508747A (ja) | 2002-03-19 |
| JP2002508747A5 JP2002508747A5 (enExample) | 2005-12-02 |
Family
ID=21936112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54741798A Pending JP2002508747A (ja) | 1997-04-30 | 1998-04-30 | 小胞複合体並びにその作製及び使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6217900B1 (enExample) |
| EP (1) | EP0986372B1 (enExample) |
| JP (1) | JP2002508747A (enExample) |
| KR (1) | KR100554344B1 (enExample) |
| CN (1) | CN1092045C (enExample) |
| AT (1) | ATE446372T1 (enExample) |
| AU (1) | AU728115C (enExample) |
| BR (1) | BR9809006B1 (enExample) |
| CA (1) | CA2285298C (enExample) |
| DE (1) | DE69841251D1 (enExample) |
| ES (1) | ES2333282T3 (enExample) |
| WO (1) | WO1998048780A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013523693A (ja) * | 2010-04-01 | 2013-06-17 | ファーマネスト・エイビイ | 熱ゲル化麻酔組成物 |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3785932B2 (ja) * | 1998-05-25 | 2006-06-14 | 日本新薬株式会社 | 核酸含有複合体製剤の製造方法 |
| EP2314700A1 (en) * | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| EP1097993A3 (en) * | 1999-11-05 | 2004-01-07 | National Institute of Advanced Industrial Science and Technology | Functional ribozyme chimeric molecules capable of sliding |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7461046B2 (en) * | 2002-02-07 | 2008-12-02 | The University Of Utah Research Foundation | Method for creating and using a treatment protocol |
| US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
| JP4868739B2 (ja) | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 核酸の送達法 |
| US20030235916A1 (en) * | 2002-06-14 | 2003-12-25 | Monahan Sean D. | Novel methods for the delivery of polynucleotides to cells |
| WO2004011624A2 (en) * | 2002-07-31 | 2004-02-05 | Nucleonics, Inc. | Double stranded rna structures and constructs, and methods for generating and using the same |
| WO2004073631A2 (en) * | 2003-02-14 | 2004-09-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| HUE042261T2 (hu) | 2003-06-12 | 2019-06-28 | Alnylam Pharmaceuticals Inc | Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| ES2362670T3 (es) | 2004-09-24 | 2011-07-11 | Alnylam Pharmaceuticals, Inc | Orientación a intermedios de replicación de hebra no codificante de virus monocatenarios por arni. |
| EP2316942B1 (en) | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| DK2094086T3 (da) * | 2006-11-08 | 2013-11-25 | Veritas Bio LLC | Indgivelse in vivo af dobbeltstrenget rna til en målcelle |
| EP2167130A2 (en) * | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| SG189772A1 (en) | 2008-04-11 | 2013-05-31 | Trubion Pharmaceuticals Inc | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2427472B1 (en) | 2009-05-05 | 2016-06-22 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| US20120148664A1 (en) | 2009-06-08 | 2012-06-14 | Miragen Therapeutics | Chemical modifications motifs for mirna inhibitors and mimetics |
| JP5995855B2 (ja) | 2010-11-05 | 2016-09-21 | ミラゲン セラピューティクス，インコーポレイテッド | 塩基修飾オリゴヌクレオチド |
| CA2817371A1 (en) | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| JP2014515024A (ja) | 2011-04-12 | 2014-06-26 | ベス イスラエル デアコネス メディカル センター， インコーポレイテッド | マイクロｒｎａ阻害剤および疾患におけるその使用 |
| WO2013037065A1 (en) | 2011-09-13 | 2013-03-21 | Ottawa Hospital Research Institute | Microrna inhibitors |
| CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| WO2014145356A1 (en) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| US10772974B2 (en) | 2013-11-18 | 2020-09-15 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for cardiac regeneration |
| WO2016022536A2 (en) | 2014-08-04 | 2016-02-11 | MiRagen Therapeutics, Inc. | Inhibitors of myh7b and uses thereof |
| MX382425B (es) | 2014-09-08 | 2025-03-13 | Miragen Therapeutics Inc | Imitadores de mir-29 y usos de los mismos |
| HK1249108A1 (zh) | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| KR20190118688A (ko) | 2015-06-05 | 2019-10-18 | 미라젠 세러퓨틱스 인코포레이티드 | 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제 |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| WO2017087486A1 (en) | 2015-11-16 | 2017-05-26 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein |
| EP3472193A4 (en) | 2016-06-20 | 2020-01-08 | The Board of Trustees of the Leland Stanford Junior University | CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION |
| UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| ES2659845B1 (es) | 2016-09-19 | 2019-01-04 | Univ Valencia | Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello |
| AR113490A1 (es) | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| WO2019178411A1 (en) | 2018-03-14 | 2019-09-19 | Beth Israel Deaconess Medical Center | Inhibitors of micro-rna 22 |
| US20220049252A1 (en) | 2018-12-10 | 2022-02-17 | Amgen Inc. | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
| PE20211225A1 (es) | 2018-12-10 | 2021-07-06 | Amgen Inc | Constructos de arni para inhibir la expresion de pnpla3 |
| US20220307022A1 (en) | 2019-05-30 | 2022-09-29 | Amgen Inc. | Rnai constructs for inhibiting scap expression and methods of use thereof |
| JP2022544238A (ja) | 2019-08-13 | 2022-10-17 | アムジエン・インコーポレーテツド | ＳＬＣ３０Ａ８発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
| AU2020399636A1 (en) | 2019-12-09 | 2022-06-02 | Amgen Inc. | RNAi constructs and methods for inhibiting LPA expression |
| US20230088509A1 (en) | 2020-05-20 | 2023-03-23 | St. Jude Children's Research Hospital | Detection of alzheimer's disease using specific biomarkers |
| KR20240004092A (ko) | 2020-06-01 | 2024-01-11 | 암젠 인크 | Hsd17b13 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법 |
| EP3929295A1 (en) | 2020-06-26 | 2021-12-29 | Universitat Pompeu Fabra | Artificial rnas for modulating rna fragments |
| WO2022036126A2 (en) | 2020-08-13 | 2022-02-17 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION |
| CA3199678A1 (en) | 2020-11-05 | 2022-05-12 | Amgen Inc. | Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs |
| WO2023278295A1 (en) | 2021-06-29 | 2023-01-05 | The Broad Institute, Inc. | Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability |
| JP2024537098A (ja) | 2021-10-05 | 2024-10-10 | アムジエン・インコーポレーテツド | オリゴヌクレオチド化合物の遺伝子サイレンシング活性を増強するための組成物及び方法 |
| EP4419682A2 (en) | 2021-10-22 | 2024-08-28 | Amgen Inc. | Rnai constructs for inhibiting gpam expression and methods of use thereof |
| US20240084301A1 (en) | 2022-07-25 | 2024-03-14 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
| EP4353823A1 (en) | 2022-10-12 | 2024-04-17 | Resalis Therapeutics S.r.l. | Inhibitors of micro-rna 22 |
| WO2024130142A2 (en) | 2022-12-16 | 2024-06-20 | Amgen Inc. | Rnai constructs for inhibiting ttr expression and methods of use thereof |
| WO2025260042A1 (en) | 2024-06-14 | 2025-12-18 | Amgen Inc. | Rnai constructs and methods for inhibiting cnr1 expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
| US5514788A (en) | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| WO1994016737A1 (en) * | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| JPH10512242A (ja) * | 1994-12-30 | 1998-11-24 | カイロン コーポレイション | 組み合わせ遺伝子送達ビヒクル |
| KR20140137679A (ko) | 2013-05-23 | 2014-12-03 | 삼성전자주식회사 | 카드 소켓 장치 |
-
1997
- 1997-04-30 US US09/402,507 patent/US6217900B1/en not_active Expired - Fee Related
-
1998
- 1998-04-30 ES ES98920077T patent/ES2333282T3/es not_active Expired - Lifetime
- 1998-04-30 CA CA 2285298 patent/CA2285298C/en not_active Expired - Fee Related
- 1998-04-30 KR KR1019997009723A patent/KR100554344B1/ko not_active Expired - Fee Related
- 1998-04-30 DE DE69841251T patent/DE69841251D1/de not_active Expired - Lifetime
- 1998-04-30 JP JP54741798A patent/JP2002508747A/ja active Pending
- 1998-04-30 AT AT98920077T patent/ATE446372T1/de not_active IP Right Cessation
- 1998-04-30 EP EP19980920077 patent/EP0986372B1/en not_active Expired - Lifetime
- 1998-04-30 AU AU72724/98A patent/AU728115C/en not_active Ceased
- 1998-04-30 BR BRPI9809006-2A patent/BR9809006B1/pt not_active IP Right Cessation
- 1998-04-30 WO PCT/US1998/008799 patent/WO1998048780A1/en not_active Ceased
- 1998-04-30 CN CN98810484A patent/CN1092045C/zh not_active Expired - Fee Related
-
2000
- 2000-04-04 US US09/542,409 patent/US6383512B1/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013523693A (ja) * | 2010-04-01 | 2013-06-17 | ファーマネスト・エイビイ | 熱ゲル化麻酔組成物 |
| US9254263B2 (en) | 2010-04-01 | 2016-02-09 | Pharmanest Ab | Thermogelling anaesthetic compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69841251D1 (de) | 2009-12-03 |
| AU728115B2 (en) | 2001-01-04 |
| BR9809006A (pt) | 2000-08-08 |
| AU7272498A (en) | 1998-11-24 |
| WO1998048780A1 (en) | 1998-11-05 |
| EP0986372A1 (en) | 2000-03-22 |
| US6217900B1 (en) | 2001-04-17 |
| ATE446372T1 (de) | 2009-11-15 |
| CN1092045C (zh) | 2002-10-09 |
| EP0986372B1 (en) | 2009-10-21 |
| EP0986372A4 (en) | 2002-06-19 |
| KR100554344B1 (ko) | 2006-02-22 |
| CA2285298A1 (en) | 1998-11-05 |
| AU728115C (en) | 2004-01-22 |
| ES2333282T3 (es) | 2010-02-18 |
| KR20010020161A (ko) | 2001-03-15 |
| CN1277549A (zh) | 2000-12-20 |
| BR9809006B1 (pt) | 2010-02-09 |
| US6383512B1 (en) | 2002-05-07 |
| CA2285298C (en) | 2008-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508747A (ja) | 小胞複合体並びにその作製及び使用法 | |
| ES2305157T3 (es) | Liposomas. | |
| JP4800485B2 (ja) | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 | |
| US7202227B2 (en) | Multifunctional molecular complexes for gene transfer to cells | |
| JP4535211B2 (ja) | コクリエート送達ビヒクル | |
| WO2002060412A2 (en) | Stabilised polymeric aerosols for pulmonary gene delivery | |
| PT1326636E (pt) | Composição de vacina | |
| AU745805B2 (en) | Compositions and methods for delivery of genetic material | |
| WO2000040273A2 (en) | Treatment of viral diseases using an interferon omega expressing polynucleotide | |
| WO2001009303A2 (en) | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER | |
| JP4723097B2 (ja) | サイトフェクチン二量体およびその使用方法 | |
| EP1257298B1 (en) | Cosmid dna constructs and methods of making and using the same | |
| WO2023169500A1 (zh) | 编码新型冠状病毒S蛋白的mRNA疫苗 | |
| Dijkstra et al. | Volume I: Molecular Biochemistry and Cellular Biology 329 | |
| AU2002242049A1 (en) | Stabilised polymeric aerosols for pulmonary gene delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050426 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081205 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081226 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090629 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091001 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20091224 |